← The Wire
SNDXNasdaq
Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
red 8-K · 90d
$1.62B
Market cap
$21.78
Last close
+2.2%
1D
+12.7%
5D
4.7M
Volume
Price · last 39 sessions+9.1%
May 4L $16.96 · H $21.78Jun 29
227
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
424B5424B5Dec 15, 2023424B5424B5Dec 14, 2023424B5424B5May 26, 2023424B5424B5Dec 7, 2022424B5424B5Dec 6, 2022424B5424B5Dec 17, 2021424B5424B5Dec 16, 2021424B5424B5Dec 9, 2021424B5424B5Dec 9, 2020424B5424B5Dec 7, 2020424B5424B5May 4, 2020424B5424B5Apr 30, 2020424B5424B5Feb 3, 2020424B5424B5Sep 10, 2019424B5424B5Mar 29, 2019424B5424B5Mar 28, 2019424B5424B5Oct 18, 2017424B5424B5May 25, 2017424B5424B5May 23, 2017
Insider Activity
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance